Evidence map›Paper›PMID 29627775›Full record

ArticleBMJ case reports2018

Acute mucocutaneous methotrexate toxicity with marked tissue eosinophilia.

Luis J Borda, Andrew Ross, Gabriel Villada, Clara Milikowski

Abstract readCase Reports
In one paragraph

Article in BMJ case reports, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.5field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 6 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

4 authors at 1 institution in 1 country.

Luis J BordaDepartment of Dermatology and Cutaneous Surgery, University of Miami School of Medicine, Miami, Florida, USA.ORCID http://orcid.org/0000-0002-3569-9005
Andrew RossDepartment of Dermatology and Cutaneous Surgery, University of Miami School of Medicine, Miami, Florida, USA.
Gabriel VilladaDepartment of Dermatology and Cutaneous Surgery, University of Miami School of Medicine, Miami, Florida, USA.
Clara MilikowskiDepartment of Pathology and Laboratory Medicine, University of Miami School of Medicine, Miami, Florida, USA.
University of Miami · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Methotrexate toxicity in mucocutaneous areas is usually not associated with tissue eosinophilia. We describe a case of acute methotrexate-induced mucocutaneous erosions with interface dermatitis and eosinophils. A 76-year-old African-American woman with a history of bullous pemphigoid on methotrexate therapy presented with lower extremity cellulitis, developing oral and cutaneous erosions during hospitalization after daily dosage of methotrexate. Shallow circular cutaneous erosions were found on chest, abdomen and limbs. Laboratory results showed pancytopaenia and elevated liver function tests. Skin biopsy revealed irregular acanthotic epidermis with interface dermatitis, individual dyskeratotic cells and superficial perivascular lymphocytic infiltrate with numerous eosinophils. Methotrexate was stopped and leucovorin was administered, leading to improvement. The histopathological changes in acute mucocutaneous toxicity range from pauci-inflammatory erosions with dyskeratotic keratinocytes to interface dermatitis and infrequently seen eosinophils. This case exemplifies that interface dermatitis with a marked eosinophilic infiltrate can be found in the setting of acute mucocutaneous methotrexate toxicity.

Indexed as

AgedDrug EruptionsEosinophiliaFemaleHumansLeucovorinMethotrexateMouth MucosaPancytopeniaPemphigoid, BullousTreatment OutcomeLeucovorinMethotrexateeosinophilic infiltrateinterface dermatitismethotrexate toxicitymucocutaneous erosions

Identifiers

PMID29627775
PMCPMC5893949
OpenAlexW2795634355

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.